Literature DB >> 34856855

Immune variants of SARS-CoV-2 could be a significant challenge for developing a pan genotype-specific vaccine.

Abhay Singh1, Sachin Kumar1.   

Abstract

The circulating variants of SARS-CoV-2 pose a threat to the public health response worldwide, especially in the case of developing countries, lacking vaccines and having compromised health-care facilities. This article highlights several recent studies conducted to determine the efficacy of COVID-19 vaccines against variants of concern. These studies comprise clinical trials and neutralization assay-based studies conducted on messenger RNA (mRNA), recombinant, viral vector-based, and inactivated vaccines.

Entities:  

Keywords:  COVID-19; genotype; pathogenic; vaccine; variants

Mesh：

Substances：

Year:  2021        PMID： 34856855      PMCID： PMC8903907          DOI： 10.1080/21645515.2021.1997487

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN： 2164-5515            Impact factor:   3.452


  11 in total

1.  Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization.

Authors:  Timothée Bruel; Etienne Simon-Lorière; Felix A Rey; Olivier Schwartz; Delphine Planas; David Veyer; Artem Baidaliuk; Isabelle Staropoli; Florence Guivel-Benhassine; Maaran Michael Rajah; Cyril Planchais; Françoise Porrot; Nicolas Robillard; Julien Puech; Matthieu Prot; Floriane Gallais; Pierre Gantner; Aurélie Velay; Julien Le Guen; Najiby Kassis-Chikhani; Dhiaeddine Edriss; Laurent Belec; Aymeric Seve; Laura Courtellemont; Hélène Péré; Laurent Hocqueloux; Samira Fafi-Kremer; Thierry Prazuck; Hugo Mouquet
Journal:  Nature       Date:  2021-07-08       Impact factor: 49.962

2.  mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar.

Authors:  Hiam Chemaitelly; Hadi M Yassine; Fatiha M Benslimane; Hebah A Al Khatib; Patrick Tang; Mohammad R Hasan; Joel A Malek; Peter Coyle; Houssein H Ayoub; Zaina Al Kanaani; Einas Al Kuwari; Andrew Jeremijenko; Anvar Hassan Kaleeckal; Ali Nizar Latif; Riyazuddin Mohammad Shaik; Hanan F Abdul Rahim; Gheyath K Nasrallah; Mohamed Ghaith Al Kuwari; Hamad Eid Al Romaihi; Mohamed H Al-Thani; Abdullatif Al Khal; Adeel A Butt; Roberto Bertollini; Laith J Abu-Raddad
Journal:  Nat Med       Date:  2021-07-09       Impact factor: 53.440

3.  Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis.

Authors:  Bryan A Johnson; Xuping Xie; Adam L Bailey; Birte Kalveram; Kumari G Lokugamage; Antonio Muruato; Jing Zou; Xianwen Zhang; Terry Juelich; Jennifer K Smith; Lihong Zhang; Nathen Bopp; Craig Schindewolf; Michelle Vu; Abigail Vanderheiden; Emma S Winkler; Daniele Swetnam; Jessica A Plante; Patricia Aguilar; Kenneth S Plante; Vsevolod Popov; Benhur Lee; Scott C Weaver; Mehul S Suthar; Andrew L Routh; Ping Ren; Zhiqiang Ku; Zhiqiang An; Kari Debbink; Michael S Diamond; Pei-Yong Shi; Alexander N Freiberg; Vineet D Menachery
Journal:  Nature       Date:  2021-01-25       Impact factor: 49.962

4.  Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant.

Authors:  Vivek Shinde; Sutika Bhikha; Zaheer Hoosain; Moherndran Archary; Qasim Bhorat; Lee Fairlie; Umesh Lalloo; Mduduzi S L Masilela; Dhayendre Moodley; Sherika Hanley; Leon Fouche; Cheryl Louw; Michele Tameris; Nishanta Singh; Ameena Goga; Keertan Dheda; Coert Grobbelaar; Gertruida Kruger; Nazira Carrim-Ganey; Vicky Baillie; Tulio de Oliveira; Anthonet Lombard Koen; Johan J Lombaard; Rosie Mngqibisa; As'ad E Bhorat; Gabriella Benadé; Natasha Lalloo; Annah Pitsi; Pieter-Louis Vollgraaff; Angelique Luabeya; Aliasgar Esmail; Friedrich G Petrick; Aylin Oommen-Jose; Sharne Foulkes; Khatija Ahmed; Asha Thombrayil; Lou Fries; Shane Cloney-Clark; Mingzhu Zhu; Chijioke Bennett; Gary Albert; Emmanuel Faust; Joyce S Plested; Andreana Robertson; Susan Neal; Iksung Cho; Greg M Glenn; Filip Dubovsky; Shabir A Madhi
Journal:  N Engl J Med       Date:  2021-05-05       Impact factor: 91.245

5.  Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19.

Authors:  Jerald Sadoff; Glenda Gray; An Vandebosch; Vicky Cárdenas; Georgi Shukarev; Beatriz Grinsztejn; Paul A Goepfert; Carla Truyers; Hein Fennema; Bart Spiessens; Kim Offergeld; Gert Scheper; Kimberly L Taylor; Merlin L Robb; John Treanor; Dan H Barouch; Jeffrey Stoddard; Martin F Ryser; Mary A Marovich; Kathleen M Neuzil; Lawrence Corey; Nancy Cauwenberghs; Tamzin Tanner; Karin Hardt; Javier Ruiz-Guiñazú; Mathieu Le Gars; Hanneke Schuitemaker; Johan Van Hoof; Frank Struyf; Macaya Douoguih
Journal:  N Engl J Med       Date:  2021-04-21       Impact factor: 176.079

6.  Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial.

Authors:  Raches Ella; Siddarth Reddy; William Blackwelder; Varsha Potdar; Pragya Yadav; Vamshi Sarangi; Vinay K Aileni; Suman Kanungo; Sanjay Rai; Prabhakar Reddy; Savita Verma; Chandramani Singh; Sagar Redkar; Satyajit Mohapatra; Anil Pandey; Pajanivel Ranganadin; Raghavendra Gumashta; Manish Multani; Shameem Mohammad; Parul Bhatt; Laxmi Kumari; Gajanan Sapkal; Nivedita Gupta; Priya Abraham; Samiran Panda; Sai Prasad; Balram Bhargava; Krishna Ella; Krishna Mohan Vadrevu
Journal:  Lancet       Date:  2021-11-11       Impact factor: 79.321

Review 7.  The Spike of Concern-The Novel Variants of SARS-CoV-2.

Authors:  Anna Winger; Thomas Caspari
Journal:  Viruses       Date:  2021-05-27       Impact factor: 5.048

8.  The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity.

Authors:  Qianqian Li; Jiajing Wu; Jianhui Nie; Li Zhang; Huan Hao; Shuo Liu; Chenyan Zhao; Qi Zhang; Huan Liu; Lingling Nie; Haiyang Qin; Meng Wang; Qiong Lu; Xiaoyu Li; Qiyu Sun; Junkai Liu; Linqi Zhang; Xuguang Li; Weijin Huang; Youchun Wang
Journal:  Cell       Date:  2020-07-17       Impact factor: 41.582

9.  SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness.

Authors:  Aziz Sheikh; Jim McMenamin; Bob Taylor; Chris Robertson
Journal:  Lancet       Date:  2021-06-14       Impact factor: 79.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.